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Aims We used virtual histology-intravascular ultrasound (VH-IVUS) to evaluate the relation between coronary plaque
characteristics and no-reﬂow in acute coronary syndrome (ACS) patients.
Methods
and results
A total of 190 consecutive ACS patients were imaged using VH-IVUS and analysed retrospectively. Angiographic no-
reﬂow was deﬁned as TIMI ﬂow grade 0, 1, and 2 after stenting. Virtual histology-intravascular ultrasound classiﬁed
the colour-coded tissue into four major components: ﬁbrotic, ﬁbro-fatty, dense calcium, and necrotic core (NC).
Thin-cap ﬁbroatheroma (TCFA) was deﬁned as focal, NC-rich ( 10% of the cross-sectional area) plaques being
in contact with the lumen in a plaque burden  40%. Of the 190 patients studied at pre-stenting, no-reﬂow was
observed in 24 patients (12.6%) at post-stenting. The absolute and %NC areas at the minimum lumen sites
(1.6+1.2 vs. 0.9+0.8 mm
2, P , 0.001, and 24.5+14.3 vs. 16.1+10.6%, P ¼ 0.001, respectively) and the absolute
and %NC volumes (30+24 vs. 16+17 mm
3, P ¼ 0.001, and 22+11 vs. 14+8%, P , 0.001, respectively) were
signiﬁcantly greater, and the presence of at least one TCFA and multiple TCFAs within culprit lesions (71 vs. 36%,
P ¼ 0.001, and 38 vs. 15%, P ¼ 0.005, respectively) was signiﬁcantly more common in the no-reﬂow group compared
with the normal-reﬂow group. In the multivariable analysis,%NC volume was the only independent predictor of no-
reﬂow (odds ratio ¼ 1.126; 95% CI 1.045–1.214, P ¼ 0.002).
Conclusion In ACS patients, post-stenting no-reﬂow is associated with plaque components deﬁned by VH-IVUS analysis with
larger NC and more TCFAs.
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Percutaneous coronary intervention (PCI) is the most common
strategy for treating acute coronary syndrome (ACS).
1–3
However, PCI fails to achieve Thrombolysis In Myocardial Infarc-
tion (TIMI)-3 ﬂow in 12–30% of cases, mainly because of the
no-reﬂow phenomenon.
4,5 Several grey-scale intravascular ultra-
sound (IVUS) studies have demonstrated several predictors of
no-reﬂow phenomenon in ACS patients.
6–10
Grey-scaleIVUSiswidelyusedtoassesscoronaryarterymorpho-
metry. However, this conventional IVUS has signiﬁcant limitations
inassessingplaquecomposition.
11,12 SpectralanalysisofIVUSradio-
frequency data [virtual histology (VH)-IVUS] can provide
quantitative information on plaque composition; it has been
validated in study of explanted human coronary segments [in that
study, necrotic core (NC) was described as necrotic calciﬁcation
and then extrapolated to NC].
13 Virtual histology-intravascular
ultrasound characterizes atherosclerotic plaque as ﬁbrotic (FT),
ﬁbro-fatty (FF), dense calcium (DC), and NC.
13,14 Several
VH-IVUS studies have demonstrated the coronary plaque com-
ponentsinACSpatients.
14–16However,sofar,fewdataareavailable
and therearecontroversiesintheassociationbetweenplaquecom-
ponents and no-reﬂow after PCI in ACS patients.
17–21 Therefore,
the purpose of the present study was to investigate the relation
between pre-procedural plaque components assessed by VH-IVUS
and no-reﬂow after stent deployment in ACS patients.
Methods
This study was a retrospective, single-centre study. A total of 2450 ACS
patients were admitted to our institute from February 2006 to January
2008. Of these, VH-IVUS was performed in 345 patients. We excluded
45 patients who did not undergo PCI and 110 patients who underwent
pre-stenting balloon angioplasty. Finally, we identiﬁed 190 ACS patients
who underwent pre-PCI VH-IVUS and stent implantation of native, de
novo coronary lesion. The presence of unstable angina was determined
by chest pain within the preceding 72 h with or without ST-T wave
changes or positive cardiac biochemical markers. The presence of
ST-segment elevation myocardial infarction was determined by
.30 min of continuous chest pain, a new ST-segment elevation
 2 mm on at least two contiguous electrocardiographic leads, and cre-
atine kinase-MB more than three times normal. The presence of
non-ST-segment elevation myocardial infarction was diagnosed by
chest pain and a positive cardiac biochemical marker without new
ST-segment elevation. We excluded patients with subacute or late
stentthrombosis, totallyoccluded lesions,restenosis afterstenting, cor-
onaryarterybypassgraftfailure,factorsassociatedwithincreasedriskof
bleeding, severe heart failure or cardiogenic shock, important systemic
disease,orserumcreatinine  2.5 mg/dL,andpatientsinwhomadequate
IVUS images could not be obtained. All patients were treated with stent
implantation: 168 patients with drug-eluting stents and 22 patients with
bare-metalstents.Theprotocolwasapprovedbytheinstitutionalreview
board.Hospitalrecordsofpatientswerereviewedtoobtaininformation
on clinical demographics.
Peripheral blood samples were obtained before IVUS study using
direct venipuncture. The blood samples were centrifuged, and serum
was removed and stored at 2708C until the assay could be performed.
Absolute creatine kinase-MB levels were determined by radioimmuno-
assay (Dade Behring Inc., Miami, FL, USA). Cardiac-speciﬁc troponin I
levels were measured using paramagnetic particles and a chemilumi-
nescent immunoenzymatic assay (Beckman, Coulter Inc., Fullerton,
CA, USA). The serum levels of total cholesterol, triglyceride, low-
density lipoprotein cholesterol, and high-density lipoprotein choles-
terol were measured by standard enzymatic methods. High-sensitivity
C-reactive protein was analysed turbidimetrically with sheep anti-
bodies against human C-reactive protein; this has been validated
against the Dade–Behring method.
22 Serum N-terminal pro-B-type
natriuretic peptide was measured using an electrochemiluminescence
sandwich immunoassay method with an Elecsys 2010 analyzer
(Roche Diagnostics, Mannheim, Germany).
No-reﬂow was deﬁned as post-PCI TIMI grade 0, 1, or 2 ﬂow in the
absence of mechanical obstruction.
5,8 Normal-reﬂow was deﬁned as
TIMI grade 3 ﬂow. On this basis, patients were divided into two
groups: a no-reﬂow group (n ¼ 24) and a normal-reﬂow group (n ¼
166). If TIMI ﬂow post-PCI was 0, 1, or 2 in the absence of angiographic
stenosis, repeated IVUS was performed to exclude the possibility of
mechanical vessel obstruction.
Coronary angiogram was analysed with validated QCA system (Phil-
lips H5000 or Allura DCI program, Philips Medical Systems, Eindhoven,
The Netherlands). With the outer diameter of the contrast-ﬁlled cath-
eter as the calibration standard, the minimal lumen diameter, reference
diameter, and lesion length were measured in diastolic frames from
orthogonal projections. Perfusion was evaluated according to TIMI
criteria.
23
All pre-PCI VH-IVUS examinations were performed after intracor-
onary administration of 300 mg nitroglycerin. A 20-MHz, 2.9F IVUS
imaging catheter (Eagle Eye, Volcano Corp, Rancho Cordova, CA,
USA) was advanced .10 mm beyond the lesion; and automated pull-
back was performed to a point .10 mm proximal to the lesion at a
speed of 0.5 mm/s. Quantitative volumetric grey-scale and VH-IVUS
analyses were performed across the entire lesion segment, and cross-
sectional analysis was performed at the minimum lumen sites and at
the largest NC sites. Grey-scale IVUS analysis was performed accord-
ing to the American College of Cardiology Clinical Expert Consensus
Document on Standards for Acquisition, Measurement and Reporting
of Intravascular Ultrasound Studies.
24 External elastic membrane
(EEM) and lumen cross-sectional areas (CSA) were measured.
Plaque plus media (P&M) CSA was calculated as EEM minus lumen
CSA; and plaque burden was calculated as P&M divided by EEM
CSA. Proximal and distal references were the single slices with the
largest lumen and smallest plaque CSAs within 10 mm proximally
and distally, but before any large side branch. Remodelling index was
the ratio of lesion site EEM CSA divided by the average of the proximal
and distal reference EEM CSA. Post-PCI, we measured the minimum
stent CSA. Stent expansion was calculated as minimum stent CSA
divided by mean reference lumen CSA. Virtual histology-intravascular
ultrasound analysis classiﬁed the colour-coded tissue into four major
components: green (FT); yellow-green (FF); white (DC); and red
(NC).
13,14 Virtual histology-intravascular ultrasound analysis was
reported in absolute amounts and as a percentage of plaque area or
volume. Thin-cap ﬁbroatheroma (TCFA) was deﬁned as a NC  10%
of plaque area in at least three consecutive frames without overlying
ﬁbrous tissue in the presence of  40% plaque burden.
14
The statistical Package for Social Sciences (SPSS) for Windows,
version 15.0 (Chicago, IL, USA) was used for all analyses. Continuous
variables were presented as the mean value+1 SD; comparisons
were conducted by student’s t-test or the Wilcoxon rank-sum test if
normality assumption was violated. Discrete variables were presented
as percentages and frequencies; comparisons were conducted by x
2
statistics or Fisher’s exact test as appropriate. Multivariable analysis
was performed to identify independent predictors of no-reﬂow
Y.J. Hong et al. 2060phenomenon. Univariable analyses were ﬁrst conducted to identify
potential risk factors for no-reﬂow. The likelihood ratio test was
used, and the variables with a P-value of ,0.2 were included in the
multivariable model. Finally, a stepdown logistic regression was per-
formed. The least signiﬁcant variable was dropped at each step until
only covariates with a P-value ,0.05 remained. A P-value ,0.05
was considered statistically signiﬁcant.
Results
Of the 190 patients studied at pre-stenting, no-reﬂow was
observed in 24 patients (12.6%) at post-stenting. The baseline
characteristics are summarized in Table 1. There were no signiﬁ-
cant differences in age, gender, clinical presentations, risk factors
for coronary artery disease, ejection fraction, serum creatinine
levels, and lipid proﬁles. There were no signiﬁcant differences in
the use of glycoprotein IIb/IIIa inhibitors and pre-PCI clopidogrel
loading. Creatine kinase-MB and cardiac-speciﬁc troponin-I levels
tended to be higher in the no-reﬂow group compared with the
normal-reﬂow group. High-sensitivity C-reactive protein and N-
terminal pro-B type natriuretic peptide levels were signiﬁcantly
higher in the no-reﬂow group compared with the normal-reﬂow
group. In-hospital mortality tended to be higher in the no-reﬂow
group compared with the normal-reﬂow group [4/24 (17%) vs.
9/166 (5%), P ¼ 0.064].
Coronary angiographic ﬁndings are summarized in Table 2.
There were no signiﬁcant differences in culprit lesions, diseased
vessel number, American College of Cardiology/American Heart
Association lesion type, TIMI ﬂow grade, stent diameter and
length, inﬂation pressure, angiographic reference diameter, and
minimal lumen diameter. However, the angiographic lesion length
and stent length were signiﬁcantly longer in the no-reﬂow group
compared with the normal-reﬂow group.
Grey-scale IVUS ﬁndings are summarized in Table 3.A tt h e
minimum lumen sites, the lumen CSA was signiﬁcantly smaller in
theno-reﬂowgroupcomparedwiththenormal-reﬂowgroup;incon-
trast, the EEM and P&M CSAs and plaque burden were signiﬁcantly
greater in the no-reﬂow group compared with the normal-reﬂow
group. Intravascular ultrasound lesion length was signiﬁcantly longer
in the no-reﬂow group compared with the normal-reﬂow group.
There were strong trends towards greater remodelling index,
greater minimum stent CSA, and greater percent stent expansion.
There were no signiﬁcant differences in the IVUS parameters at the
proximal and distal reference sites between both groups.
At the minimum lumen sites, the absolute and %NC areas and
absolute DC area were signiﬁcantly greater in the no-reﬂow
group compared with the normal-reﬂow group; conversely%FF
...............................................................................................................................................................................
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Table 1 Baseline characteristics
No-reﬂow (n 5 24) Normal-reﬂow (n 5 166) P-value
Age (years) 60.1+14.4 60.5+12.2 0.9
Male gender (%) 14 (58) 109 (66) 0.5
Clinical presentation 0.6
Unstable angina (%) 13 (54) 98 (59)
Non-ST-segment elevation MI (%) 6 (25) 28 (17)
ST-segment elevation MI (%) 5 (21) 40 (24)
Diabetes mellitus (%) 6 (25) 32 (19) 0.5
Hypertension (%) 17 (71) 87 (52) 0.090
Smoking (%) 13 (54) 82 (49) 0.7
Prior MI (%) 1 (4) 5 (3) 0.8
Ejection fraction (%) 62+96 2 +9 1.0
Glycoprotein IIb/IIIa inhibitor use (%) 7 (29) 39 (23) 0.5
Pre-PCI clopidogrel loading (%) 23 (96) 160 (96) 1.0
White blood cells (10
3/mm
3) 8.9+3.3 8.5+2.9 0.5
Haemoglobin (g/dL) 13.9+1.6 14.3+1.6 0.3
Platelet count (10
3/mm
3) 238+97 221+66 0.4
Creatine kinase-MB (U/L) 22.8+59.6 12.7+14.6 0.14
Cardiac-speciﬁc troponin-I (ng/mL) 13.0+61.1 4.0+6.5 0.13
Creatinine (mg/dL) 0.9+0.2 0.9+0.2 0.6
Glucose (mg/dL 160+54 140+41 0.15
Total cholesterol (mg/dl) 200+56 187+48 0.4
Triglyceride (mg/dL) 141+69 116+63 0.17
LDL-cholesterol (mg/dL) 133+47 122+41 0.4
HDL-cholesterol (mg/dL) 48+94 6 +12 0.6
hs-CRP (mg/dL) 1.8+0.8 0.8+0.3 0.021
NT-pro-BNP (pg/mL) 526+533 237+293 0.029
Coronary plaque components and no-reﬂow 2061area was signiﬁcantly smaller in the no-reﬂow group compared
with the normal-reﬂow group (Figure 1). At the largest NC sites,
the absolute and %NC areas and absolute DC area were signiﬁ-
cantly greater in the no-reﬂow group compared with the normal-
reﬂow group; conversely %FT and FF areas were signiﬁcantly
smaller in the no-reﬂow group compared with the normal-reﬂow
group (Figure 2). The absolute and %NC and DC volumes were
signiﬁcantly greater in the no-reﬂow group compared with
the normal-reﬂow group; conversely %FT and FF volumes were
signiﬁcantly smaller in the no-reﬂow group compared with the
normal-reﬂow group (Figure 3). At the proximal reference sites,
the%NC and FT areas were signiﬁcantly greater in the no-reﬂow
group compared with the normal-reﬂow group; conversely %FF
area was signiﬁcantly smaller in the no-reﬂow group compared
with the normal-reﬂow group (Figure 4A). At the distal reference
sites, the%NC and DC areas were signiﬁcantly greater in the
no-reﬂow group compared with the normal-reﬂow group
(Figure 4B). The presence of at least one TCFA and multiple
TCFAs within culprit lesions were more common in the no-reﬂow
group than in the normal-reﬂow group (Figure 5).
Multivariable analysis was performed to identify independent
predictors of no-reﬂow phenomenon. Univariable analysis was
ﬁrst conducted to identify potential predictors for no-reﬂow. All
variables with P , 0.2 in univariable analysis (hypertension,
cardiac speciﬁc troponin-I, serum glucose, triglyceride, high-
sensitivity C-reactive protein, N-terminal pro-B-type natriuretic
peptide, type B2/C lesion, stent diameter, minimum lumen site
EEM CSA and plaque burden, IVUS lesion length, stent expansion,
and volumetric VH-IVUS parameters: absolute DC and NC
volumes, relative FT, FF, DC, and NC volumes) were tested for
multivariable analysis.%NC volume was the only independent pre-
dictor of no-reﬂow after stent deployment in ACS patients (odds
ratio ¼ 1.126; 95% CI 1.045–1.214, P ¼ 0.002).
Discussion
The present VH-IVUS study demonstrates that ACS patients with
no-reﬂow phenomenon have more NC-containing lesions and
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Table 2 Coronary angiographic ﬁndings
No-reﬂow
(n 5 24)
Normal-reﬂow
(n 5 166)
P-value
Culprit lesion (%) 0.6
Left main 0 (0) 2 (1)
Left anterior
descending
8 (33) 59 (36)
Left circumﬂex 5 (21) 50 (30)
Right 11 (46) 55 (33)
Diseased vessel number
(%)
0.5
1 6 (25) 53 (32)
2 13 (54) 88 (50)
3 5 (21) 25 (18)
ACC/AHA lesion type
(%)
0.097
B1 8 (33) 73 (44)
B2 12 (50) 70 (42)
C 4 (17) 23 (14)
TIMI ﬂow grade (%) 0.5
0 0 (0) 0 (0)
1 0 (0) 0 (0)
2 7 (29) 37 (22)
3 17 (71) 129 (78)
Stent type (%) 0.9
Drug-eluting stents 21 (88) 147 (89)
Bare-metal stents 3 (12) 19 (11)
Stent diameter (mm) 3.25+0.68 3.18+0.56 0.16
Stent length (mm) 25.8+10.3 22.1+9.4 0.036
Inﬂation pressure (atm) 13.6+3.6 13.0+2.9 0.3
Post-PCI TIMI ﬂow
grade (%)
,0.001
0 3 (13) 0 (0)
1 4 (17) 0 (0)
2 17 (80) 0 (0)
3 0 (0) 166 (100)
Reference diameter
(mm)
3.29+0.87 3.22+0.75 0.3
Pre-MLD (mm) 0.62+0.31 0.65+0.51 0.5
Lesion length (mm) 18+12 14+8 0.023
Post-MLD (mm) 3.20+0.62 3.15+0.58 0.11
................................................................................
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Table 3 Grey-scale intravascular ultrasound ﬁndings
No-reﬂow
(n 5 24)
Normal-reﬂow
(n 5 166)
P-value
Proximal reference
EEM CSA (mm
2) 15.8+7.8 15.6+5.8 0.4
Lumen CSA (mm
2) 9.8+4.5 9.8+3.5 1.0
P&M CSA (mm
2) 6.0+3.2 5.8+3.2 0.4
Plaque burden (%) 38+93 7 +9 0.6
Minimum lumen site
EEM CSA (mm
2) 16.2+6.0 15.6+5.8 0.042
Lumen CSA (mm
2) 3.4+2.4 4.0+2.1 0.021
P&M CSA (mm
2) 12.8+4.8 11.6+4.3 0.013
Plaque burden (%) 79+12 74+16 0.008
IVUS lesion length (mm) 22+13 18+12 0.020
Distal reference
EEM CSA (mm
2) 15.2+5.7 15.0+5.0 0.4
Lumen CSA (mm
2) 9.3+3.6 9.6+3.1 0.2
P&M CSA (mm
2) 5.9+2.8 5.4+2.7 0.14
Plaque burden (%) 39+13 36+12 0.16
Remodelling index 1.05+0.38 1.02+0.23 0.068
Minimum stent CSA
(mm
2)
8.8+3.4 8.4+2.9 0.087
Stent expansion (%) 92+19 87+17 0.076
Y.J. Hong et al. 2062more TCFA lesions compared with ACS patients with normal-
reﬂow after stent deployment. Therefore, we should consider
intensiveuseofglycoproteinIIb/IIIainhibitorsandhighdosesofanti-
platelet agents as well as optimal stent implantation to reduce distal
embolization and no-reﬂowphenomenon after stent deployment in
ACS patients with greater NC-containing lesions.
No-reﬂow phenomenon was attributable to the embolization of
thrombus and plaque debris that results from mechanical fragmen-
tation of the vulnerable plaque by PCI.
6–8,25 Several grey-scale
IVUS studies have demonstrated that thrombus formation,
6,7
positive remodelling,
8,9 greater plaque burden,
6,7 and decreased
post-PCI plaque volume
7,10 were the independent predictors of
no-reﬂow phenomenon in ACS patients.
Virtual histology-intravascular ultrasound has the potential to
provide detailed qualitative and quantitative information, and it
can identify four speciﬁc plaque components. Several studies
have demonstrated the coronary plaque components assessed by
VH-IVUS in ACS patients.
14–16 Rodriguez-Granillo et al.
14
reported that VH-IVUS identiﬁed TCFA as a more prevalent
ﬁnding in ACS patients than in stable angina patients. Thin-cap
ﬁbroatheroma is the precursor of plaque rupture, which accounts
for a majority of coronary thrombi and coronary death.
26–29 Hong
et al.
15 reported that the amounts of NC were larger and the
amounts of FT and FF plaque were less in ACS patients compared
with stable angina patients. Missel et al.
16 reported that the percen-
tage of NC and its ratio to DC in diseased coronary segments are
positively associated with a high-risk ACS presentation. Plaque
Figure 1 The absolute (A) and relative (B) plaque components
at the minimum lumen site. Virtual histology-intravascular ultra-
sound analysis classiﬁed the colour-coded tissue into four
major components: green [ﬁbrotic (FT)]; yellow-green [ﬁbro-
fatty (FF)]; white [dense calcium (DC); and red [necrotic core
(NC)]. At the minimum lumen site, the absolute and relative
necrotic core areas and the absolute dense calcium area were sig-
niﬁcantly greater in the no-reﬂow group than in the normal-
reﬂow group; conversely the relative ﬁbro-fatty area was signiﬁ-
cantly smaller in the no-reﬂow group than in the normal-reﬂow
group.
Figure 2 The absolute (A) and relative (B) plaque components
at the largest necrotic core site. Virtual histology-intravascular
ultrasound analysis classiﬁed the colour-coded tissue into four
major components: green [ﬁbrotic (FT)]; yellow-green [ﬁbro-
fatty (FF)]; white [dense calcium (DC); and red [necrotic core
(NC)]. At the largest necrotic core site, the absolute and relative
necrotic core areas and absolute dense calcium area were signiﬁ-
cantly greater in the no-reﬂow group than in the normal-reﬂow
group; conversely relative ﬁbrotic and ﬁbro-fatty areas were sig-
niﬁcantly smaller in the no-reﬂow group than in the normal-
reﬂow group.
Coronary plaque components and no-reﬂow 2063composition plays a role in the plaque disruption and thrombosis,
which leads to acute coronary events.
26,27,30,31 Lesions with a large
lipid core have a higher risk for disruption than sclerotic
plaques.
31–33
There are controversies in the association between plaque com-
ponents and no-reﬂow or slow-ﬂow phenomenon after PCI in
ACS patients.
17–21 Kawaguchi et al.
18 reported that NC volume
clearly predicted distal embolization after stent deployment in
patients with ST-segment elevation myocardial infarction as com-
pared with FT, FF, DC, and total plaque volumes. Kawamoto
et al.
19 reported that the NC component identiﬁed with
VH-IVUS was related to liberation of small embolic particles
during coronary stenting, which resulted in the poorer recovery
of coronary ﬂow velocity reserve. However, Bae et al.
20 reported
that patients with slow ﬂow had more FT and FF volumes, not NC
volumes, at the time of the primary PCI for acute myocardial
infarction. Nakamura et al.
21 reported that VH-IVUS showed a
trend towards larger percentage of FF plaque volume in the
no-reﬂow group than in the normal-reﬂow group. In the present
study, we demonstrated the NC-rich plaque as assessed by
VH-IVUS was independently associated with no-reﬂow, and NC
content through the entire lesion segment (NC volume) was
more important than NC content at a single coronary site, such
as minimum lumen site or largest NC site. Moreover, the culprit
Figure 3 The volumetric absolute (A) and relative (B) plaque
components. Virtual histology-intravascular ultrasound analysis
classiﬁed the colour-coded tissue into four major components:
green [ﬁbrotic (FT)]; yellow-green [ﬁbro-fatty (FF)]; white
[dense calcium (DC); and red [necrotic core (NC)]. The absolute
and relative necrotic core and dense calcium volumes were sig-
niﬁcantly greater in the no-reﬂow group than in the normal-
reﬂow group; conversely relative ﬁbrotic and ﬁbro-fatty
volumes were signiﬁcantly smaller in the no-reﬂow group than
in the normal-reﬂow group.
Figure 4 The relative plaque components at the proximal (A)
and distal (B) reference sites. Virtual histology-intravascular ultra-
sound analysis classiﬁed the colour-coded tissue into four major
components: green [ﬁbrotic (FT)]; yellow-green [ﬁbro-fatty (FF)];
white [dense calcium (DC); and red [necrotic core (NC)]. At the
proximal reference sites, the relative necrotic core and ﬁbrotic
areas were signiﬁcantly greater in the no-reﬂow group than in
the normal-reﬂow group; conversely relative ﬁbro-fatty area
was signiﬁcantly smaller in the no-reﬂow group than in the
normal-reﬂow group. At the distal reference sites, the relative
necrotic core and dense calcium areas were signiﬁcantly greater
in the no-reﬂow group than in the normal-reﬂow group.
Y.J. Hong et al. 2064lesion TCFAs were observed more frequently in the no-reﬂow
group than in the normal-reﬂow group. The NC components
contain fragile tissues, such as lipid deposition with foam cells,
intramural bleeding, and cholesterol crystals, so they can be
easily liberated as small emboli by mechanical fragmentation
during coronary stenting. Our results from the present study
suggest that NC-rich plaque should be considered as an important
predictor of distal embolization and no-reﬂow during stenting
procedures.
Limitations
First, this was a retrospective single-centre study. The results of
this study should be veriﬁed by further prospective investigation.
Secondly, this study was based on a small number of patients
with no-reﬂow, raising the possibility of selection bias. Thirdly,
we did not attempt to differentiate between atherosclerotic
plaque and thrombus because VH-IVUS could not determine the
presence of thrombus. This may obscure the identiﬁcation of
TCFA. Fourth, we excluded the patients with serious conditions
such as totally occluded coronary lesions, increased risk of bleed-
ing, severe heart failure, cardiogenic shock, important systemic
disease, or renal dysfunction. Thus, the present study might not
represent the whole spectrum of ACS patients. Fifth, we have
used model-building procedures to assess the prognostic value
of the variables of interest on no-reﬂow. There is an increased
probability that chance predictors are included in the ﬁnal model
because of the high amount of testing. And, the strength of the
association of true predictors with no-reﬂow can vary at each
step depending on which (true and chance) predictors are included
at that step.
Clinical implications
We used VH-IVUS to evaluate the relation between coronary
plaque components and no-reﬂow phenomenon in 190 ACS
patients. No-reﬂow was observed in 24 patients (12.6%) at post-
stenting. The absolute and%NC volumes were signiﬁcantly
greater in the no-reﬂow group compared with the normal-reﬂow
group. The presence of at least one TCFA and multiple TCFAs
within culprit lesions was more common in the no-reﬂow group
compared with the normal-reﬂow group. In the multivariable
analysis,%NC volume was the only independent predictor of
no-reﬂow. Virtual histology-intravascular ultrasound analysis
demonstrates that post-stenting no-reﬂow is associated with
plaque components deﬁned by VH-IVUS analysis with larger NC
and more TCFAs in ACS patients.
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